Catalent Appoints Appoints New Asia Pacific President
Catalent Pharma Solutions recently announced it has named David Heyens in the new role of President of Catalent Asia Pacific. Reporting directly to Catalent’s President and CEO, John Chiminski, Mr. Heyens will drive Catalent’s growth in the region following the company’s recent expansion into China, and will build on Catalent’s well-established regional operations in Japan, Australia, and Singapore.
“This appointment comes at an important moment in our business, as we launch our two new joint ventures in China, for softgel technologies and clinical supplies, and focus more growth resources in Asia Pacific,” said Mr. Chiminski. “Bringing Dave’s proven leadership to this region is hugely beneficial for both our customers and our business.”
Replacing Mr. Heyens as the President of Catalent Softgel Technologies will be Aris Gennadios, PhD. Also reporting to Mr. Chiminski, Dr. Gennadios will have full strategic responsibility for the market-leading global softgel development, delivery, and supply business with 10 global manufacturing facilities that deliver the leading share of global pharmaceutical, generic, and consumer health softgel products to markets worldwide.
“Aris is an outstanding leader and a widely respected industry veteran, known for his expertise and passion for delivering better treatments for patients across an ever- expanding set of challenging molecules in softgel drug delivery technology” said Mr. Chiminski. “We are very excited to have him join our executive team and extend the momentum and growth that we are driving in our flagship business.”
David Heyens was named President of Catalent’s Softgel Technologies business in June 2007. Since joining Catalent in 1995, he has served in a variety of capacities, including as President of Packaging Services, Senior Vice President of Global Sales and Marketing, President of North America Softgel Technologies, and as General Manager for the Canadian softgel business. Prior to joining Catalent, he held leadership roles in sales and marketing at Baxter and Procter & Gamble.
Dr. Gennadios began his pharmaceutical industry career in 1996 as an R&D scientist in softgel technology. In 2002, he joined Catalent in business development for both advanced technologies and development solutions. After holding several business development roles of increasing responsibility, he assumed an operational leadership position as General Manager of the company’s Somerset, NJ, site. In 2010, Dr. Gennadios became Vice President and General Manager of Catalent’s Rx Softgel Technologies business, and became Vice President and General Manager of the overall global Softgel Technologies business in 2012.
Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. For more information, visit www.catalent.com.
Total Page Views: 1423
